跳至主要内容
临床试验/IRCT20210612051548N3
IRCT20210612051548N3尚未招募2 期

The efficiency of endoradiotherapy with 177Lu-Trastuzumab in patients with resistant or relapsed HER2-positive breast cancer

Boushehr University of Medical Sciences0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
Female

入选标准

  • Age =18 years
  • Patients with confirmed HER2-positive breast cancer using 68Ga-Trastuzumab PET/CT
  • Eastern Cooperative Oncology Group Performance Status (ECOG) = 2
  • Having hematologic parameters as: (i) Absolute neutrophil count = 1000 cells/mm3; (ii) Platelet count = 100,000/mm3; (iii) Hemoglobin = 9 g/dL
  • Signed informed consent form

排除标准

  • Pregnant woman
  • Inability to provide written informed consent.
  • Patients with known sensitivity or contraindication to Herceptin.
  • The patient had an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  • Patients have psychiatric illness/social situations that would interfere with compliance with study requirements

研究者

发起方
Boushehr University of Medical Sciences

相似试验